FDA grants approval for Amylyx’s Relyvrio to treat ALS
Pharmaceutical Technology
OCTOBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients with amyotrophic lateral sclerosis (ALS). An oral, fixed-dose medicine, Relyvrio is also approved with conditions in Canada such as Albrioza to treat ALS.
Let's personalize your content